| abstract |
An ophthalmologically acceptable collagen containing aqueous composition is disclosed. The composition contains collagen and is a flowable liquid at temperatures below mammalian eye temperature (32°C to 42°C) and forms a gelled sustained release matrix after administration to the mammalian eye. The composition is comprised of ophthalmologically acceptable collagen material, a pharmaceutically active non-steroidal antiinflammatory drug, optionally an antibiotic, a buffer, a nonionic ethoxylated alkylphenol surfactant, a quaternary ammonium preservative, a tonicifier, a chelating agent, and optional excipients in an aqueous carrier. The collagen in the composition undergoes a change from a flowable liquid to a gelled matrix after the formulation is administered to the eye. The gelled matrix of the formulation traps and physically holds the drug in the matrix. When applied, the gel will remain in place in the cul-de-sac of the eye substantially longer than liquid formulations and will allow for a sustained release method of delivery of the drug to the eye. The drug release from the matrix and the drug half life are such that the formulation allows for once a day or even less frequent dosing which increases the convenience and improves patient compliance. |